Bio-FD&C Co

Bio-FD&C Co Debt/EBITDA

The Total Debt to EBITDA Ratio of Bio-FD&C Co (251120.KQ) as of Oct 21, 2026 is 0.25. In the previous year, Total Debt to EBITDA Ratio was 0.23 — a change of 8.15% (higher).

Debt/EBITDA

0.25

YoY

8.15%

Last updated:

Total Debt to EBITDA Ratio of Bio-FD&C Co is 2024 0.25 . Total Debt to EBITDA Ratio of Bio-FD&C Co was 2023 0.23 . It decreases by 8.15% higher compared to the previous year.

The Bio-FD&C Co Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
10.69 KRW
Jan 1, 2019
0.88 KRW
Jan 1, 2020
0.80 KRW
Jan 1, 2021
0.52 KRW
Jan 1, 2022
0.62 KRW
Jan 1, 2023
0.23 KRW
Jan 1, 2024
0.25 KRW
The Bio-FD&C Co Debt/EBITDA history
YEARDebt/EBITDAYoY
0.25+8.15%
0.23-63.17%
0.62+18.42%
0.52-34.86%
0.80-8.51%
0.88-91.80%
10.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-FD&C Co Stock analysis

What does Bio-FD&C Co do? Bio-FD&C Co., Ltd. develops bio and health technologies, focusing on manufacturing and selling soybean callus culture extract, clock stem cell, centella asiatica, callus extract, aloe barbadensis phytoplaceta extract, prunus mume phytoplacenta extract, secale cereale adventitious root extract, and acanthopanax koreanum adventitious root culture extract. These products serve as key materials for cosmeceuticals, health functional foods, and pharmaceuticals, targeting companies in the cosmetics, health supplement, and pharmaceutical industries. The company generates revenue through direct sales of these specialized extracts to manufacturers who incorporate them into their final products. The firm's product portfolio includes unique bioactive compounds like centella asiatica and prunus mume phytoplacenta extract, which are used in high-value applications within the cosmeceutical and pharmaceutical sectors. By supplying these specialized ingredients, Bio-FD&C Co., Ltd. caters to clients seeking natural, plant-based solutions for product development. Its focus on extract-based materials positions it as a supplier for companies developing innovative health and beauty products. Bio-FD&C Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-FD&C Co stock

Total Debt to EBITDA Ratio of Bio-FD&C Co is 0.25 in 2024.

Total Debt to EBITDA Ratio of Bio-FD&C Co changed from 0.23 to 0.25, representing a 8.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Bio-FD&C Co since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Bio-FD&C Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bio-FD&C Co

All Key Metrics — Bio-FD&C Co